Stem cell findings may offer answers for some bladder defects and disease

PUBLIC RELEASE DATE:

21-Mar-2014

Contact: Charles Casey charles.casey@ucdmc.ucdavis.edu 916-734-9048 University of California - Davis Health System

(SACRAMENTO, Calif.) For the first time, scientists have succeeded in coaxing laboratory cultures of human stem cells to develop into the specialized, unique cells needed to repair a patient's defective or diseased bladder.

The breakthrough, developed at the UC Davis Institute for Regenerative Cures and published today in the scientific journal Stem Cells Translational Medicine, is significant because it provides a pathway to regenerate replacement bladder tissue for patients whose bladders are too small or do not function properly, such as children with spina bifida and adults with spinal cord injuries or bladder cancer.

"Our goal is to use human stem cells to regenerate tissue in the lab that can be transplanted into patients to augment or replace their malfunctioning bladders," said Eric Kurzrock, professor and chief of the division of pediatric urologic surgery at UC Davis Children's Hospital and lead scientist of the study, which is titled "Induction of Human Embryonic and Induced Pluripotent Stem Cells into Urothelium."

To develop the bladder cells, Kurzrock and his UC Davis colleagues investigated two categories of human stem cells. In their key experiments, they used induced pluripotent stem cells (iPS cells), which were derived from lab cultures of human skin cells and umbilical blood cells that had been genetically reprogrammed to convert to an embryonic stem cell-like state.

If additional research demonstrates that grafts of bladder tissue grown from human stem cells will be safe and effective for patient care, Kurzrock said that the source of the grafts would be iPS cells derived from a patient's own skin or umbilical cord blood cells. This type of tissue would be optimal, he said, because it lowers the risk of immunological rejection that typifies most transplants.

In their investigation, Kurzrock and his colleagues developed a protocol to prod the pluripotent cells into becoming bladder cells. Their procedure was efficient and, most importantly, the cells proliferated over a long period of time a critical element in any tissue engineering application.

"What's exciting about this discovery is that it also opens up an array of opportunities using pluripotent cells," said Jan Nolta, professor and director of the UC Davis Stem Cell program and a co-author on the new study. "When we can reliably direct and differentiate pluripotent stem cells, we have more options to develop new and effective regenerative medicine therapies. The protocols we used to create bladder tissue also provide insight into other types of tissue regeneration."

The rest is here:
Stem cell findings may offer answers for some bladder defects and disease

Stem cell findings may offer answers for some bladder defects, disease

For the first time, scientists have succeeded in coaxing laboratory cultures of human stem cells to develop into the specialized, unique cells needed to repair a patient's defective or diseased bladder.

The breakthrough, developed at the UC Davis Institute for Regenerative Cures and published today in the scientific journal Stem Cells Translational Medicine, is significant because it provides a pathway to regenerate replacement bladder tissue for patients whose bladders are too small or do not function properly, such as children with spina bifida and adults with spinal cord injuries or bladder cancer.

"Our goal is to use human stem cells to regenerate tissue in the lab that can be transplanted into patients to augment or replace their malfunctioning bladders," said Eric Kurzrock, professor and chief of the division of pediatric urologic surgery at UC Davis Children's Hospital and lead scientist of the study, which is titled "Induction of Human Embryonic and Induced Pluripotent Stem Cells into Urothelium."

To develop the bladder cells, Kurzrock and his UC Davis colleagues investigated two categories of human stem cells. In their key experiments, they used induced pluripotent stem cells (iPS cells), which were derived from lab cultures of human skin cells and umbilical blood cells that had been genetically reprogrammed to convert to an embryonic stem cell-like state.

If additional research demonstrates that grafts of bladder tissue grown from human stem cells will be safe and effective for patient care, Kurzrock said that the source of the grafts would be iPS cells derived from a patient's own skin or umbilical cord blood cells. This type of tissue would be optimal, he said, because it lowers the risk of immunological rejection that typifies most transplants.

In their investigation, Kurzrock and his colleagues developed a protocol to prod the pluripotent cells into becoming bladder cells. Their procedure was efficient and, most importantly, the cells proliferated over a long period of time -- a critical element in any tissue engineering application.

"What's exciting about this discovery is that it also opens up an array of opportunities using pluripotent cells," said Jan Nolta, professor and director of the UC Davis Stem Cell program and a co-author on the new study. "When we can reliably direct and differentiate pluripotent stem cells, we have more options to develop new and effective regenerative medicine therapies. The protocols we used to create bladder tissue also provide insight into other types of tissue regeneration."

UC Davis researchers first used human embryonic stem cells obtained from the National Institutes of Health's repository of human stem cells. Embryonic stem cells can become any cell type in the body (i.e., they are pluripotent), and the team successfully coaxed these embryonic stem cells into bladder cells. They then used the same protocol to coax iPS cells made from skin and umbilical cord blood into bladder cells, called urothelium, that line the inside of the bladder. The cells expressed a very unique protein and marker of bladder cells called uroplakin, which makes the bladder impermeable to toxins in the urine.

The UC Davis researchers adjusted the culture system in which the stem cells were developing to encourage the cells to proliferate, differentiate and express the bladder protein without depending upon signals from other human cells, said Kurzrock. In future research, Kurzrock and his colleagues plan to modify the laboratory cultures so that they will not need animal and human products, which will allow use of the cells in patients.

Kurzrock's primary focus as a physician is with children suffering from spina bifida and other pediatric congenital disorders. Currently, when he surgically reconstructs a child's defective bladder, he must use a segment of their own intestine. Because the function of intestine, which absorbs food, is almost the opposite of bladder, bladder reconstruction with intestinal tissue may lead to serious complications, including urinary stone formation, electrolyte abnormalities and cancer. Developing a stem cell alternative not only will be less invasive, but should prove to be more effective, too, he said.

Read more:
Stem cell findings may offer answers for some bladder defects, disease

Joseph Purita, M.D. and Maritza Novas, R.N., M.S.N. of Global Stem Cells Group, Inc. and Bioheart CSO Kristin Comella …

Miami (PRWEB) March 20, 2014

Joseph Purita, M.D. and Maritza Novas, R.N., M.S.N. of Global Stem Cells Group Inc., and Bioheart, Inc. Chief Scientific Officer Kristin Comella will be featured speakers at the 31st American Association of Orthopedic Medicine Annual Conference (AAOM) Conference and Scientific Seminar in Clearwater Beach, Florida April 9-12, 2014. Co-sponsored by the American Board of Quality Assurance and Utilization Review Physicians, Inc. (ABQAURP), the conference, titled Sports, Spine and Beyond: Latest Advances in Regenerative Orthopedic Medicine, will focus on the newest breakthroughs in the field of orthopedic medicine.

Purita, Novas and Comella will present the latest advances in stem cell therapies in sports medicine, regenerative orthopedic medicine and interventional pain medicine, including techniques for extracting stem cells from adipose tissue to use in patient treatments. Purita is a pioneer in the use of stem cells in orthopedics and founder of the Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida. Novas is a lead trainer and part of the research and development team for Stem Cell Training, a Global Stem Cells Group subsidiary.

Comella has more than 15 years experience in cell culturing and developing stem cell therapies for degenerative diseases and experience in corporate entities, with expertise in regenerative medicine, training and education, research, product development and senior management.

The conference will explore advances in other non-traditional treatments in sports and regenerative orthopedic medicine including manual medicine, nutrition, bioidentical hormone replacement therapy, musculoskeletal ultrasound and more. The goal of the AAOM Conference is to bring sports medicine physicians, PM&R specialists (physiatrists), family medicine physicians, orthopedic surgeons, neurologists and interventional pain physiciansincluding anesthesiologists and osteopathic pain physiciansthe latest state-of-the-art techniques and technologies to help treat their patients performance-related pain and injuries, overuse syndromes and chronic pain.

For more information on the 31st AAOM Annual Conference and Scientific Seminar, visit the AAOM website.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

To learn more about Global Stem Cells Group, Inc.s companies and for investor information, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

Read this article:
Joseph Purita, M.D. and Maritza Novas, R.N., M.S.N. of Global Stem Cells Group, Inc. and Bioheart CSO Kristin Comella ...

Stem cells created from a drop of blood: DIY finger-prick technique opens door for extensive stem cell banking

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have developed a method to generate human induced pluripotent stem cells (hiPSCs) from a single drop of finger-pricked blood. The method also enables donors to collect their own blood samples, which they can then send to a laboratory for further processing. The easy access to blood samples using the new technique could potentially boost the recruitment of greater numbers and diversities of donors, and could lead to the establishment of large-scale hiPSC banks.

By genetic reprogramming, matured human cells, usually blood cells, can be transformed into hiPSCs. As hiPSCs exhibit properties remarkably similar to human embryonic stem cells, they are invaluable resources for basic research, drug discovery and cell therapy. In countries like Japan, USA and UK, a number of hiPSC bank initiatives have sprung up to make hiPSCs available for stem cell research and medical studies.

Current sample collection for reprogramming into hiPSCs include invasive measures such as collecting cells from the bone marrow or skin, which may put off many potential donors. Although hiPSCs may also be generated from blood cells, large quantities of blood are usually required. In the paper published online on the Stem Cell Translational Medicine journal, scientists at IMCB showed for the first time that single-drop volumes of blood are sufficient for reprogramming into hiPSCs. The finger-prick technique is the world's first to use only a drop of finger-pricked blood to yield hiPSCs with high efficiency. A patent has been filed for the innovation.

The accessibility of the new technique is further enhanced with a DIY sample collection approach. Donors may collect their own finger-pricked blood, which they can then store and send it to a laboratory for reprogramming. The blood sample remains stable for 48 hours and can be expanded for 12 days in culture, which therefore extends the finger-prick technique to a wide range of geographical regions for recruitment of donors with varied ethnicities, genotypes and diseases.

By integrating it with the hiPSC bank initiatives, the finger-prick technique paves the way for establishing diverse and fully characterised hiPSC banking for stem cell research. The potential access to a wide range of hiPSCs could also replace the use of embryonic stem cells, which are less accessible. It could also facilitate the set-up of a small hiPSC bank in Singapore to study targeted local diseases.

Dr Loh Yuin Han Jonathan, Principal Investigator at IMCB and lead scientist for the finger-prick hiPSC technique, said, "It all began when we wondered if we could reduce the volume of blood used for reprogramming. We then tested if donors could collect their own blood sample in a normal room environment and store it. Our finger-prick technique, in fact, utilised less than a drop of finger-pricked blood. The remaining blood could even be used for DNA sequencing and other blood tests."

Dr Stuart Alexander Cook, Senior Consultant at the National Heart Centre Singapore and co-author of the paper, said "We were able to differentiate the hiPSCs reprogrammed from Jonathan's finger-prick technique, into functional heart cells. This is a well-designed, applicable technique that can unlock unrealized potential of biobanks around the world for hiPSC studies at a scale that was previously not possible."

Prof Hong Wanjin, Executive Director at IMCB, said "Research on hiPSCs is now highly sought-after, given its potential to be used as a model for studying human diseases and for regenerative medicine. Translational research and technology innovations are constantly encouraged at IMCB and this new technique is very timely. We hope to eventually help the scientific community gain greater accessibility to hiPSCs for stem cell research through this innovation."

Story Source:

The above story is based on materials provided by A*STAR. Note: Materials may be edited for content and length.

View original post here:
Stem cells created from a drop of blood: DIY finger-prick technique opens door for extensive stem cell banking

:: 20, Mar 2014 :: A*STAR SCIENTISTS CREATE STEM CELLS FROM A DROP OF BLOOD

The DIY finger-prick technique opens door for extensive stem cell banking

1. Scientists at A*STARs Institute of Molecular and Cell Biology (IMCB) have developed a method to generate human induced pluripotent stem cells (hiPSCs) from a single drop of finger-pricked blood. The method also enables donors to collect their own blood samples, which they can then send to a laboratory for further processing. The easy access to blood samples using the new technique could potentially boost the recruitment of greater numbers and diversities of donors, and could lead to the establishment of large-scale hiPSC banks.

3. Current sample collection for reprogramming into hiPSCs include invasive measures such as collecting cells from the bone marrow or skin, which may put off many potential donors. Although hiPSCs may also be generated from blood cells, large quantities of blood are usually required. In the paper published online on the Stem Cell Translational Medicine journal, scientists at IMCB showed for the first time that single-drop volumes of blood are sufficient for reprogramming into hiPSCs. The finger-prick technique is the worlds first to use only a drop of finger-pricked blood to yield hiPSCs with high efficiency. A patent has been filed for the innovation.

4. The accessibility of the new technique is further enhanced with a DIY sample collection approach. Donors may collect their own finger-pricked blood, which they can then store and send it to a laboratory for reprogramming. The blood sample remains stable for 48 hours and can be expanded for 12 days in culture, which therefore extends the finger-prick technique to a wide range of geographical regions for recruitment of donors with varied ethnicities, genotypes and diseases.

5. By integrating it with the hiPSC bank initiatives, the finger-prick technique paves the way for establishing diverse and fully characterised hiPSC banking for stem cell research. The potential access to a wide range of hiPSCs could also replace the use of embryonic stem cells, which are less accessible. It could also facilitate the set-up of a small hiPSC bank in Singapore to study targeted local diseases.

6. Dr Loh Yuin Han Jonathan, Principal Investigator at IMCB and lead scientist for the finger-prick hiPSC technique, said, It all began when we wondered if we could reduce the volume of blood used for reprogramming. We then tested ifdonors could collect their own blood sample in a normal room environment and store it. Our finger-prick technique, in fact, utilised less than a drop of finger-pricked blood. The remaining blood could even be used for DNA sequencing and other blood tests.

Read the original here:
:: 20, Mar 2014 :: A*STAR SCIENTISTS CREATE STEM CELLS FROM A DROP OF BLOOD

159 Regenerative Medicine Group Launches Hong Kong Tour for Rebirth

HONG KONG--(BUSINESS WIRE)--Hong Kongs renowned 159 Regenerative Medicine Group, a group of life science experts specializing in aging and anti-aging and regenerative medicine, today announces its Hong Kong Tour for Rebirth, a week long trip to Hong Kong that will extend, protect and enhance the lives of those who take part.

Bringing the Groups Nobel Prize-based iPS stem cell technology and its superior medical beauty and anti-aging healthcare services together with the beauty of Hong Kong the Pearl of the Orient the tour will offer participants a once-in-a-lifetime chance to enjoy an entirely new way of living. This incredible experience involves a course of Autologous Hematopoietic Stem Cell transplantation, followed by exposure to Hong Kongs world-class landmarks and multinational cuisines.

Beginning with an introduction to the Groups services at its state-of-the-art Anti-Aging Centre and with the participants health at the focus of every one of the seven days, the tour will be a professional and personalized anti-aging service, which will not only enhance the participants quality of life, but also prolong their lifespans.

Highlights of the tour include:

The total value of this unique tour is HK $600,000. For a limited time, the tour is available at the preferential price of HK $390,000.

About the Group

159 Regenerative Medicine Group, a subsidiary of Hong Kong Life Sciences and Technologies Group Limited (Stock Code: 8085), has been developing and perfecting stem cell treatment methods for 15 years. Based on the Nobel Prize-based iPS stem cell technology, in 2012 the Group developed a series of Autologous Hematopoietic Stem Cell production, anti-aging and medical treatments, providing a one-stop service which protects, produces and preserves stem cells. The Group also offers professional medical consultation, GMP laboratory testing, application Autologous Hematopoietic Stem Cell technology, and several unique 360-degree human aging detection techniques to assess the aging process.

Hotline: 852-3588-0900

Read this article:
159 Regenerative Medicine Group Launches Hong Kong Tour for Rebirth

Stem cell research gets $500,000 boost

UC Merced professor Kara McCloskey was recently awarded a highly competitive $500,000 grant to continue research in human stem cell biology, as part of an effort to enhance stem cell research in California.

In February, the California Institute for Regenerative Medicine approved more than $27million for Basic Biology V Awards, and McCloskeys grant is included. The leads for this effort include Stanford University and the Salk Institute for Biological Studies.

In her laboratory, McCloskey and her students are using stem cells to engineer cardiovascular tissues that could someday be used to repair damaged blood vessels or heart tissue.

Specifically, they are producing highly specialized cells that have not been the focus of much research to date the endothelial cells found at the tips and in the stalks, including phalanx endothelial cells, of blood vessels and cells that could help repair a damaged heart.

The phalanx cells exhibit anti-inflammatory properties, and the ones in the tips and stalks contribute to angiogenesis, the new growth of blood vessels, said McCloskey, who teachers in the School of Engineering.

The two-year grant will help support her laboratory, including five undergrads, five graduate students and one post-doctoral scholar as they gather the data that takes them to the next step building 3-D models of the vessels through which fluid can flow.

Before implantation, we will first build and test the functional blood vessels to make sure they work properly, she said.

Stem cell research has made huge strides since California made the research part of its constitutional right with the passage of Proposition 71 in 2004. But there are still issues with getting the human body to accept the new cells, even once the specialized cells are physically available to repair damaged and-or diseased cells and tissue.

Aluma credits new work to UC academic approach

Graduate school is a constant state of discovery, something UC Merced alumna Jackie Shay credits for her current passion: fungus.

Read more:
Stem cell research gets $500,000 boost

FDA's Regulation of Regenerative Medicine including Stem Cell Treatments, Tissue Engineering, Etc.

Course Description: Regenerative medicine focuses on harnessing the power of ones own stem cells and regenerative capabilities to restore function to damaged cells, tissues and organs. In April 2006, the U.S. Food and Drug Administrations (FDA) implemented regulations governing the use of human cells, tissues, and cellular and tissue-based products (HCT/Ps) in humans including bone, ligament, skin, dura mater, stem cells, cartilage cells, and various other cellular and tissue-based products. Currently, there is an ongoing debate in the industry on how such therapies should be regulated by FDA or under the practice of medicine, under federal law or state law, and as drugs or simply biologics.

This 2-day interactive seminar on FDA regulations of regenerative medicine will cover:

-How FDA is currently regulating regenerative therapies and products intended for both human and veterinary use. -The distinction being made between human regenerative products and their regulation as drugs, biologics, devices, and combination products. -The New Drug Application (NDA) and the Biologic License Application (BLA) review and approval processes including a discussion of available options, application components, relevant meetings, timing, costs and approval requirements. -The option for obtaining designation and approval as Orphan Drug Product. -Designing and conducting appropriate clinical trials to support the approval of regenerative therapies. -FDAs regulation of some regenerative medicine products and accessories as Medical Devices. -The Current Good Manufacturing Practices (cGMPs) and Good Laboratory Practices (GLPs) being applied by FDA to human regenerative products. -The labeling and marketing of regenerative products and therapies. -The potential for enforcement action and recommendations for mitigating that risk. -The current regulation of veterinary cellular treatments including autologous, allogeneic and xenogeneic cellular products in the United States.

Learning Objectives: Participants who attend this course on FDA regulation of regenerative medicines will leave with a comprehensive understanding of:

-How FDA regulates regenerative treatments and therapies? -The HCT/P Criteria and Minimal Manipulation Standard. -The Drug and Biological Approval Process. -Regenerative Products as Medical Devices. -How to Design Appropriate Clinical Trials? -Applicable cGMPs and cGLPs. -Marketing Exclusivity and Patent Restoration. -Product Labeling, Marketing and Advertising. -FDA and other Federal Agency Enforcement Action. -The Regulation of Veterinary Regenerative Medicine. -The New Animal Drug Application (NADA) Process. -Veterinary User Fees and Waivers.

Who will benefit: This course is designed for professionals in stem cell, biotech, pharmaceutical and animal drug companies, veterinary hospitals and clinics. The following personnel will find this session valuable:

-Senior quality managers -Quality professionals -Regulatory professionals -Compliance professionals -Production supervisors -Manufacturing engineers -Production engineers -Design engineers -Labelers and Private Labelers -Contract Manufacturers -Importers and Custom Agents -U.S. Agents of Foreign Corporations -Process owners -Quality engineers -Quality auditors -Document control specialists -Record retention specialists -Medical affairs -Legal Professionals -Financial Advisors and Institutional Investors -Consultants, Inspectors and cGMP Experts

Read more:
FDA's Regulation of Regenerative Medicine including Stem Cell Treatments, Tissue Engineering, Etc.

Academic social network ResearchGate aids debunking of stem cell study

5 hours ago Mar. 14, 2014 - 3:36 AM PDT

ResearchGate, the 4-million-strong academic social network, has just scored a major victory in its quest to turn the research process upside-down its platform proved instrumental in the debunking of a major stem cell study, which on Friday resulted in a very apologetic roll-back from the Japanese institute that put out the original study.

The original study came out in Nature, the peer-reviewed scientific journal, earlier this year. It purported to show that it was possible to turn normal blood cells into master stem cells by dipping them in a mild acid solution. Stem cells hold great promise for the future of medicine, but theres a lot of controversy around current harvesting techniques, particularly when embryos are involved, and this would have provided a terrific workaround.

Unfortunately, while the Riken institutes research promised great things, other researchers found themselves unable to reproduce the results. One, a Hong Kong professor of regenerative medicine named Kenneth Lee, used his ResearchGate profile to publish his and his students findings, demonstrating a failure to get this technique to work.

There had been a good deal of grumbling about the Nature paper, but Lees ResearchGate publication provided the final straw and Riken admitted the original Nature papers contained errors. One of the key researchers there has now had her research suspended, and investigations are underway at both Riken and Nature.

This is what I was dreaming of, ResearchGate CEO Ijad Madisch told me. Indeed, Madisch has long advocated the advantages of post-review over pre-peer review.

Rather than the traditional system, where a paper is submitted to a journal like Nature and pored over for months by a couple of reviewers, he wants to see a system where all research is published openly and immediately not only does this bring more eyes to the research, but it also means that unsuccessful results get as good an airing as the successful ones. Thats something that should save other researchers an awful lot of time.

Bill Gates likes this approach, which is why he has poured millions into ResearchGate. And, although the discussion around it occurred in more places than just ResearchGate, the stem cell episode provides a good deal of validation.

According to Madisch, researchers who have found it difficult to reproduce the results of published papers have generally had trouble getting as much attention as those behind the published paper the press, certainly, are keener to trumpet a study that has been peer-reviewed than something that may come from a hater and that journalists feel unable to evaluate themselves.

The excitement around Lees activities on ResearchGate led the startup to speed up the completion of a new feature called Open Review, which is designed to make it easier for users to give open feedback to papers published on the network. The feature combines a structured feedback mechanism with commenting facilities.

The rest is here:
Academic social network ResearchGate aids debunking of stem cell study

New cell line should accelerate embryonic stem cell research

1 hour ago by Michael Mccarthy Dr. Carol Ware at work in her laboratory at the Institute for Stem Cell and Regenerative Medicine. Credit: Bryan Donohue

Researchers at the University of Washington have successfully created a line of human embryonic stem cells that have the ability to develop into a far broader range of tissues than most existing cell lines.

"These cells will allow us to gain a much greater understanding of normal embryonic development and have the real potential for use in developing ways to grow new tissues and organs for transplantation," said Carol Ware, a professor in the UW Department of Comparative Medicine and lead author of a paper describing the new cell line appearing in the March 10 issue of the journal Proceedings of the National Academy of Sciences.

The cells, called nave embryonic stem cells, normally appear at the earliest stages of embryonic development and so retain the ability to differentiate in all the different types of cells of the human bodya capacity called pluripotency.

Researchers had been able to develop naive cells using mouse embryonic stem cells but to create naive human embryonic stem cells has required inserting a set of genes that force the cells to behave like naive cells.

While these "transgenic" cells are valuable research tools, the presence of the artificially introduced genes meant the cells will not develop as normal embryonic cells would nor could they be safely used to create tissues and organs for transplantation.

In an article, Ware and her colleagues from the UW Institute for Stem Cell and Regenerative Medicine describe how they successfully created a line of naive human embryonic stem cells without introducing an artificial set of genes.

They first took embryonic stem cells that are slightly more developed, called primed stem cells, and grew them in a medium that contained factors that switched them backor "reverse toggled" themto the naive state.

They then used the reverse toggled cells to develop a culture medium that would keep them in the naive state and create a stable cell line for study and research.

Then having worked out how to maintain the cells in the naive state, Ware and her colleagues harvested naive cells directly from donated human embryos and cultured them in the maintenance medium to see if they could create a stable cell line that had not undergone reverse toggling. After many tries, they succeeded.

See original here:
New cell line should accelerate embryonic stem cell research